ENTA—Mavyret scripts for week ending 10/6/17 (according to IMS)….
TRx: 526, +6.7% vs prior week
NRx: 351, +2.0% vs prior week
We are now ten weeks into the US launch, and the phenomenal week-over-week growth rates seen in prior weeks appear to be moderating.
(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”